Preeclampsia: What Does the Father Have to Do with It?

Current Hypertension Reports

Volumn 17, Issue 8, 2015, Pages

  Kappaatsi V ^a   Felekos, I ^a   Siristatidis, C ^b   Kasioni, S ^c   Drakontaidis, A ^c   Farmakides, G ^c   Makris, T ^c   Aggeli, C ^a   Nihoyannopoulos, P ^a   Tousoulis, D ^a   Kallikazaros, I ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c HELENA VENIZELOU HOSPITAL   (Greece)

Author keywords

Father; Paternal; Preeclampsia

Indexed keywords

HLA G ANTIGEN; INTEGRIN; SPERM ANTIGEN;

CELL INVASION; CYTOKINE PRODUCTION; CYTOTROPHOBLAST; DISEASE ASSOCIATION; FAMILY HISTORY; FETOPLACENTAL UNIT; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MATERNAL HYPERTENSION; MOLECULAR IMPRINTING; NIDATION; NULLIPARA; PATHOGENESIS; PLACENTA CIRCULATION; PREECLAMPSIA; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEMINAL PLASMA; SYSTEMATIC REVIEW; TROPHOBLAST; FEMALE; PARENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANCY;

FEMALE; HUMANS; PARENTS; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 84935034983     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0576-7     Document Type: Review

References (34)

1. Villar J, Say L, Gulmezoglu AM, Meraldi M, Lindheimer MD, Betran AP, et al. Eclampsia and pre-eclampsia: a health problem for 2000 years. In: Critchly H, MacLean A, Poston L, Walker J, editors. Pre-eclampsia. London: RCOG Press; 2003. p. 189–207.
2. Ronsmans C, Graham W. Maternal mortality: who, when, where, and why. Lancet. 2006;368(9542):1189–200.
3. Lindheimer M, Taler S, Cunningham F. ASH position paper: hypertension in pregnancy. J Clin Hypertens. 2009;11(4):214–25.
4. Tannetta D, Sargent I. Placental disease and the maternal syndrome of preeclampsia: missing links? Curr Hypertens Rep. 2013;15(6):590–9.
5. National Institute for Health and Clinical Excellence (NICE) Hypertension in pregnancy, The management of hypertensive disorders during pregnancy, Issued: August 2010 last modified: January 2011, NICE clinical guideline 107 guidance.nice.org.uk/cg107.
6. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel J, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the world health organization multicountry survey on maternal and newborn health. BJOG: Int J Obstet Gy. 2014;121:14–24. Secondary analysis of a large cross-sectional study assessing the outcomes of hypertensive disorders during pregnancy.
7. Wang A, Rana S, Karumanchi S. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology. 2009;24(3):147–58.
8. Dekker G, Sibai B. Etiology and pathogenesis of preeclampsia: current concepts. AJOG. 1998;179(5):1359–75.
9. Wheeler T, Elcock C, Anthony F. Angiogenesis and the placental environment. Placenta. 1995;16(3):289–96.
10. Hynes R. The impact of molecular biology on models for cell adhesion. Bioessays. 1994;16(9):663–9.
11. Lorentzen B, Endresen M, Clausen T, Henriksen T. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertens Pregnancy. 1994;13(1):103–9.
12. Alexander BT, Bennett WA, Khalil RA, Granger JP. Preeclampsia: linking placental ischemia with cardiovascular-renal dysfunction. News Physiol Sci. 2001;16:282–6.
13. Wang Y, Alexander J. Placental pathophysiology in preeclampsia. Pathophysiology. 2000;6(4):261–70.
14. Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody “87G” and anti-cytokeratin antibody “CAM5.2. Am J Reprod Immunol. 1996;36(6):349–58.
15. Zhao S, Gu X, Groome LJ, et al. Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia. Reprod Sci. 2009;16:970–9.
16. Graici I, Wagner S, Weissgerber T, et al. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int. 2014;86(2):275–85.
17. Lashley E, Meuleman T, Claas F. Beneficial or harmful effect of antipaternal human leukocyte antibodies on pregnancy outcome? A systematic review and meta-analysis. Am J Reprod Immunol. 2013;70(2):87–103. A meta-analysis describing the effects of antipaternal antibodies on pregnancy complications.
18. Hiby S. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200(8):957–65.
19. Saftlas AF, Rubenstein L, Prater K, Harland KK, Field E, Triche EW. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol. 2014;101–102:104–10.
20. Levron Y, Dviri M, Segol I, Yerushalmi G, Hourvitz A, Orvieto R, et al. The ‘immunologic theory’ of preeclampsia revisited: a lesson from donor oocyte gestations. Am J Obstet Gynecol. 2014;211(4):383.e1–5. A retrospective cohort study exploring he prevalence of placental complications in patients conceived through donor versus autologous oocytes.
21. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol. 2003;59(2):161–73.
22. Kho E, McCowan L, North R, Roberts C, Chan E, Black M, et al. Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol. 2009;82(1):66–73.
23. Saftlas A. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 2003;157(12):1108–14.
24. Sharkey D, Macpherson A, Tremellen K, Robertson S. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod. 2007;13(7):491–501.
25. Wang J, Knottnerus A, Schuit G, Norman R, Chan A, Dekker G. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet. 2002;359(9307):673–4.
26. Robertson S, Ingman W, O'Leary S, Sharkey D, Tremellen K. Transforming growth factor β—a mediator of immune deviation in seminal plasma. J Reprod Immunol. 2002;57(1–2):109–28.
27. Hernández-Valencia M, Saldaña Quezada L, Alvarez Muñoz M, Valdez Martínez E. Barrier family planning methods as risk factor which predisposes to preeclampsia. Ginecol Obstet Mex. 2000;68:333–8.
28. Harlap S, Paltiel O, Deutsch L, Knaanie A, Masalha S, Tiram E, et al. Paternal age and preeclampsia. Epidemiology. 2002;13(6):660–7.
29. García-Ortiz L, Gutiérrez-Salinas J, Galaviz-Hernández C, et al. Probable association between preeclampsia/eclampsia and paternal age: a pilot study. Ginecol Obstet Mex. 2011;79(4):190–5.
30. Alderman BW, Sperling RS, Daling JR. An epidemiological study of the immunogenetic aetiology of pre-eclampsia. Br Med J. 1986;292(6517):372–4.
31. Caughey AB, Stotland NE, Washington AE, Escobar GJ. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol. 2005;106(1):156–61.
32. de Jongh BE, Paul DA, Hoffman M, Locke R. Effects of pre-pregnancy obesity, race/ethnicity and prematurity. Matern Child Health J. 2014;18(3):511–7. doi:10.1007/s10995-013-1296-8.
33. Nilsson E, SalonenRos H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 2004;111(3):200–6.
34. Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. J Reprod Immunol. 2011;89(2):126–32. A concise review highlighting the immune mechanisms involved in the pathogenesis of preeclampsia.